Addex Therapeutics announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia. The data were published in the journal, Neuropharmacology, under the title Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models. There is an urgent need to identify targets and design effective therapeutics for dystonia due to the current lack of effective treatment options. In addition, the data suggest there are common mechanistic bases and signaling pathways impaired in different forms of dystonia, highlighting the potential of dipraglurant as a novel therapeutic avenue for the treatment of dystonias. Testing this hypothesis in the clinic is warranted". In these studies, the researchers showed that chronic dipraglurant administration was able to rescue loss of long-term synaptic depression (LTD).